Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06388694 · ClinicalTrials.gov registry record · NA

Pharmacist Management of Attention Deficit Hyperactivity Disorder Medication Refill Requests

A NA study of Attention-deficit Hyperactivity, sponsored by Kaiser Permanente.

Completed
Registry status
NA
Development phase
315
Enrollment target
1
Study location

NCT06388694 is a NA study of Attention-deficit Hyperactivity that has completed, run by Kaiser Permanente. The registered enrollment target is 315 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06388694, a NA study of Attention-deficit Hyperactivity, has completed, sponsored by Kaiser Permanente.

COMPLETED
Registry status
NA
Development phase
315 participants
Enrollment target
1
Study location

Study Summary

This cluster randomized trial will compare pharmacist management of secure message requests for refills of attention deficit hyperactivity medications with primary care physician management regarding quality of care, timeliness of service, and parent care experience.

Interventions

  • OTHER Pharmacist Care
  • OTHER Primary Care Physician Care

Study Locations (1)

California

  • Kaiser Permanente Northern California - Oakland

Trial Details

FieldValue
Enrollment Target 315 participants
Start Date 2024-05-06
Est. Completion 2024-07-31
Phase NA

Sponsor

Kaiser Permanente

294 total trials

What the Registry Record Tells You About NCT06388694

The ClinicalTrials.gov registry entry for NCT06388694 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Attention-deficit Hyperactivity appearing as the primary indexed condition, and to 2 interventions - of which Pharmacist Care is the first listed.

NCT06388694 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06388694 about?

NCT06388694 is a clinical study titled "Pharmacist Management of Attention Deficit Hyperactivity Disorder Medication Refill Requests". This cluster randomized trial will compare pharmacist management of secure message requests for refills of attention deficit hyperactivity medications with primary care physician management regarding quality of care, timeliness of service, and parent care experience.

What is the current status of trial NCT06388694?

This trial is currently completed. It is a NA study. The enrollment target is 315 participants. The study started on 2024-05-06. Estimated completion is 2024-07-31.

What conditions does trial NCT06388694 study?

This clinical trial studies the following conditions: Attention-deficit Hyperactivity.

What interventions are being tested in trial NCT06388694?

The interventions under investigation include: Pharmacist Care (OTHER), Primary Care Physician Care (OTHER).

Who is sponsoring clinical trial NCT06388694?

This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06388694 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.